[ET Net News Agency, 20 February 2024] BofA lowered the target price for CSPC Pharma
(01093) to HKD5.9 from HKD6.5 and maintained the "underperform" rating.
The research house said it slightly cuts the long-term revenue forecast due to
escalating domestic competition. (RC)